S
Sverre E. Kjeldsen
Researcher at University of Oslo
Publications - 771
Citations - 95426
Sverre E. Kjeldsen is an academic researcher from University of Oslo. The author has contributed to research in topics: Blood pressure & Left ventricular hypertrophy. The author has an hindex of 94, co-authored 735 publications receiving 89059 citations. Previous affiliations of Sverre E. Kjeldsen include University of Michigan & Cornell University.
Papers
More filters
Journal ArticleDOI
Cardiovascular morbidity and mortality in hypertensive patients with atrial fibrillation: The LIFE study
Kristian Wachtell,Björn Hornestam,Mika Lehto,David J. Slotweiner,Eva Gerdts,Peter Aurup,Björn Dahlöf,Hans Ibsen,Stevo Julius,Sverre E. Kjeldsen,Markku S. Nieminen,Jens Rokkedal,Richard B. Devereaux +12 more
Journal ArticleDOI
Aging and urinary vasopressin excretion in healthy men
Ingrid Os,Sverre E. Kjeldsen,Arne Westheim,Ingvar Åkesson,Ivar Eide,John Skjøtø,Ingvar Hjermann,Paul Leren +7 more
TL;DR: The present results suggest that age-related impairment of renal concentrating capacity is compensated for by increasing circulating plasma vasopressin, and may be another compensatory mechanism for decreased urinary concentrating ability.
Journal ArticleDOI
Predictors of abdominal adipose tissue compartments: 18-year follow-up of young men with and without family history of diabetes.
Sigrid Nordang Skårn,Sigrid Nordang Skårn,Heidi B. Eggesbø,Arnljot Flaa,Sverre E. Kjeldsen,Sverre E. Kjeldsen,Morten Rostrup,Cathrine Brunborg,Henrik M. Reims,Tonje A. Aksnes +9 more
TL;DR: The data suggest that the traditional cardiovascular risk markers BMI, HDL cholesterol and family history of diabetes are long-term predictors of the different abdominal adipose tissue compartments from young towards middle age in healthy men.
Journal ArticleDOI
Treatment of hypertension in patients with type-2 diabetes mellitus.
Sverre E. Kjeldsen,Ingrid Os,Csaba Farsang,Jean Michel Mallion,Lennart Hansson,Peter Sleight +5 more
Journal ArticleDOI
Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Anne-Christine Ruwald,Bo Westergaard,Thomas Sehestedt,Sverre E. Kjeldsen,Lars H Lindholm,Kristian Wachtell,Richard B. Devereux,Hans Ibsen,Markku S. Nieminen,Björn Dahlöf,Michael H. Olsen +10 more
TL;DR: The beneficial effect of losartan versus atenolol-based antihypertensive treatment on pulse pressure, HDL-C, UACR, and Cornell and Sokolow–Lyon voltage were not more pronounced in patients older than67 years compared to patients younger than 67 years.